KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Esperion Therapeutics (ESPR) Accumulated Depreciation & Amortization (2016 - 2025)

Esperion Therapeutics filings provide 9 years of Accumulated Depreciation & Amortization readings, the most recent being $2.2 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 5.06% to $2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.2 million, a 5.06% increase, with the full-year FY2025 number at $2.2 million, up 5.06% from a year prior.
  • Accumulated Depreciation & Amortization hit $2.2 million in Q4 2025 for Esperion Therapeutics, up from $2.1 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $2.6 million in Q4 2022 to a low of $2.0 million in Q4 2023.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $2.1 million (2024), compared with a mean of $2.2 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 30.55% in 2021 and later fell 21.13% in 2023.
  • Esperion Therapeutics' Accumulated Depreciation & Amortization stood at $2.1 million in 2021, then rose by 24.38% to $2.6 million in 2022, then fell by 21.13% to $2.0 million in 2023, then rose by 3.08% to $2.1 million in 2024, then rose by 5.06% to $2.2 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $2.2 million (Q4 2025), $2.1 million (Q4 2024), and $2.0 million (Q4 2023) per Business Quant data.